Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

  • Potent antibody drug combinations identified
  • Candidate antibodies could be used to treat and protect against SARSCoV-2 infections
  •  Antibody combinations differentiated from others currently being investigated
  • IONTAS a part of UK Biotech Consortium

The UK BioIndustry Association Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID19 has today reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”.

The Taskforce has developed an accelerated and rigorous multifaceted approach to create a pool of over 600 novel candidates and identified a set of antibodies with the greatest potential. These candidate antibodies are the first to be selected for the next stage of development, following assessment by collaborators for potency.

Read full Press Release here: